Citius Oncology, Inc. (CTOR)
Oxford Ledge is still expanding full research coverage of CTOR. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Citius Oncology develops targeted oncology therapies, with its lead product LYMPHIR approved for treating rare cutaneous T-cell lymphoma.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-01
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-15
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Other material event; Financial statements and exhibits 2026-05-06
- 8-K Other material event; Financial statements and exhibits 2026-04-29
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CTOR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CTOR in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.